1. Home
  2. DCOY vs REVB Comparison

DCOY vs REVB Comparison

Compare DCOY & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$0.78

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.62

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCOY
REVB
Founded
N/A
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DCOY
REVB
Price
$0.78
$1.62
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
6.0M
1.8M
Earning Date
03-23-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$1.41
52 Week High
$34.65
$54.96

Technical Indicators

Market Signals
Indicator
DCOY
REVB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
DCOY
REVB

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: